Cargando…

Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC

BACKGROUND: The combination of bevacizumab and chemotherapy is still one of the standard treatments for advanced non-small-cell lung cancer (NSCLC) patients in the new era of targeted therapy. Although a high level of baseline lactate dehydrogenase (LDH) was found to predict survival benefit from be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Butuo, Li, Cheng, Guo, Meiying, Shang, Shuheng, Li, Xiaogang, Xie, Peng, Sun, Xindong, Yu, Jinming, Wang, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166744/ https://www.ncbi.nlm.nih.gov/pubmed/30310292 http://dx.doi.org/10.2147/OTT.S171566

Ejemplares similares

The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients
por: Li, Butuo, et al.
Publicado: (2019)

Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis
por: Guo, Meiying, et al.
Publicado: (2019)

Multiple Immune Features-Based Signature for Predicting Recurrence and Survival of Inoperable LA-NSCLC Patients
por: Guo, Meiying, et al.
Publicado: (2020)

Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases
por: Shang, Shuheng, et al.
Publicado: (2018)

Integrated multi-dimensional deep neural network model improves prognosis prediction of advanced NSCLC patients receiving bevacizumab
por: Li, Butuo, et al.
Publicado: (2023)

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review
por: Liu, Zhichao, et al.
Publicado: (2018)

Prognostic Value of a Nomogram Based on the Dynamic Albumin-to-Alkaline Phosphatase Ratio for Patients with Extensive-Stage Small-Cell Lung Cancer
por: Li, Butuo, et al.
Publicado: (2020)

Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review
por: Bao, Youting, et al.
Publicado: (2018)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

The Value of CBCT-based Tumor Density and Volume Variations in Prediction of Early Response to Chemoradiation Therapy in Advanced NSCLC
por: Wen, Qiang, et al.
Publicado: (2017)

Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases
por: Li, Butuo, et al.
Publicado: (2020)

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer
por: Li, Butuo, et al.
Publicado: (2022)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
por: Li, Xuanzong, et al.
Publicado: (2021)

Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report
por: Ding, Xingchen, et al.
Publicado: (2017)

Prognostic Values of LDH and CRP in Cervical Cancer
por: Wang, Han, et al.
Publicado: (2020)

Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2014)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?
por: Xiu, Weigang, et al.
Publicado: (2022)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma
por: Xu, Yiyue, et al.
Publicado: (2022)

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial
por: Giampieri, Riccardo, et al.
Publicado: (2017)

The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population
por: Li, Chujun, et al.
Publicado: (2021)

Clinical predictive value of naïve and memory T cells in advanced NSCLC
por: Zhang, Guan, et al.
Publicado: (2022)

Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model
por: Qiao, Tianyun, et al.
Publicado: (2021)

Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer
por: Hu, Chen, et al.
Publicado: (2020)

Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy
por: Svaton, Martin, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen
por: Geng, Nan, et al.
Publicado: (2021)

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients
por: Chen, Dawei, et al.
Publicado: (2016)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Liu, Jie, et al.
Publicado: (2019)

Special Issue: Layered Double Hydroxides (LDH) and LDH-Based Hybrid Composites
por: Matusik, Jakub
Publicado: (2021)

The Interactions Between Three Typical PPCPs and LDH
por: Li, Erwei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q4gue5q240g6s57v9rrvjlki5c